DiscoveryProbe™ FDA-approved Drug Library: High-Throughput Screening and Mechanistic Discovery

Executive Summary: The DiscoveryProbe™ FDA-approved Drug Library (SKU: L1021) is a curated set of 2,320 bioactive compounds, each with regulatory approval or pharmacopeial status, for robust high-throughput and high-content screening applications (product info). Compounds span diverse mechanisms, including receptor modulation, enzyme inhibition, and signal pathway regulation. The library has enabled identification of inhibitors of necroptosis, such as saracatinib targeting MLKL, supporting translational research in inflammation and oncology (Li et al., 2024). Each compound is provided as a 10 mM DMSO solution, with stability verified for up to 24 months at -80°C. Ready-to-use formats and barcoded tracking facilitate automated workflows and minimize handling errors.

Biological Rationale

Clinically approved drugs have well-characterized safety and pharmacokinetic profiles. Utilizing such compounds in screening accelerates the identification of repurposable therapeutics and novel targets (see Translating Mechanistic Insight to Therapeutic Impact). The DiscoveryProbe™ FDA-approved Drug Library aggregates molecules with established efficacy, encompassing multiple therapeutic classes (e.g., oncology, metabolic, neurodegenerative). This approach ensures relevance to human disease and streamlines progression from hit to lead.

Mechanistically annotated libraries enable assays to probe specific pathways, such as kinase signaling, necroptosis, and GPCR modulation. For example, necroptosis—a form of programmed cell death involving MLKL and RIPK3—has emerged as a target in inflammation and cancer (Li et al., 2024). Screening with approved drugs can uncover novel inhibitors or activators applicable to these mechanisms.

Mechanism of Action of DiscoveryProbe™ FDA-approved Drug Library

The DiscoveryProbe™ library includes compounds acting as:

• Receptor agonists and antagonists (e.g., beta-blockers, opioid modulators)
• Enzyme inhibitors (e.g., kinase, protease, and phosphodiesterase inhibitors)
• Ion channel modulators (e.g., calcium and potassium channel blockers)
• Signal pathway regulators (e.g., MAPK/ERK, PI3K/AKT, NF-κB pathway modulators)

Saracatinib, a member of this library, was recently shown to inhibit necroptosis by interfering with MLKL phosphorylation and oligomerization, representing a direct modulation of a programmed cell death pathway (Li et al., 2024). Other compounds, such as doxorubicin and metformin, provide established benchmarks for cytotoxic and metabolic modulation in screening campaigns.

Evidence & Benchmarks

• Saracatinib inhibits TNF-induced necroptosis in multiple cell types by binding MLKL, as confirmed by molecular docking and thermal shift assays (Li et al., 2024).
• Mutation of the saracatinib-binding site (Gln343Ala) in MLKL reduces the drug's inhibitory effect, demonstrating target specificity (Li et al., 2024).
• In an imiquimod-induced psoriasis mouse model, saracatinib blocked MLKL phosphorylation and attenuated inflammatory responses in vivo (Li et al., 2024).
• High-throughput screening of the DiscoveryProbe™ FDA-approved Drug Library accelerates drug repositioning, as detailed in strategic reviews (see DiscoveryProbe: Accelerating Drug Repositioning).
• Compounds are provided in pre-dissolved 10 mM DMSO solutions, with verified stability for 12 months at -20°C and 24 months at -80°C under standard laboratory conditions (manufacturer data).

Compared with prior reviews (see Driving High-Throughput Discovery), this article updates the mechanistic context by highlighting MLKL-targeted necroptosis modulation and the role of regulatory-approved compound diversity in translational workflows.

Applications, Limits & Misconceptions

Applications:

• High-throughput screening (HTS) for cytotoxicity, target engagement, and phenotypic changes.
• High-content screening (HCS) for morphological profiling and pathway analysis.
• Drug repositioning to uncover new indications for known molecules.
• Mechanistic interrogation in cancer, neurodegenerative, and inflammatory disease models.
• Validation of pathway-specific inhibitors, such as MLKL modulators in necroptosis research.

Limits:

• Library is limited to compounds with regulatory approval or pharmacopeial listing; experimental or investigational compounds are excluded.
• Compounds are supplied in DMSO; aqueous incompatibility or precipitation may occur in certain assay formats.
• Some compounds may exhibit off-target effects not fully characterized in all biological contexts.

Common Pitfalls or Misconceptions

• Misconception: All compounds are selective for a single target.
  Clarification: Many drugs act on multiple targets or have polypharmacology profiles (Li et al., 2024).
• Pitfall: Assuming DMSO-solubilized drugs are compatible with all cell types.
  Clarification: DMSO can be cytotoxic above 0.5-1% v/v; dilution optimization is required.
• Misconception: Regulatory approval guarantees efficacy in all new indications.
  Clarification: Clinical efficacy must be revalidated in each new context (see DiscoveryProbe: Accelerating Drug Repositioning).
• Pitfall: Overlooking storage conditions.
  Clarification: Solutions are stable for 12 months at -20°C and 24 months at -80°C; deviations can reduce compound integrity (product info).
• Misconception: Screening results are immediately translatable to clinical outcomes.
  Clarification: In vitro findings require validation in relevant disease models and clinical studies.

Workflow Integration & Parameters

The DiscoveryProbe™ FDA-approved Drug Library is available in 96-well, deep-well, and 2D barcoded tube formats, supporting automation and error-free sample tracking. Each compound is pre-dissolved at 10 mM in DMSO, compatible with most HTS/HCS platforms. Plate layouts are designed for direct transfer to robotic liquid handlers. Thermal stability is validated for 12 months at -20°C and 24 months at -80°C. Shipping options include blue ice or ambient temperature, depending on volume and customer requirements (specifications).

For optimal screening, recommended DMSO concentrations should not exceed 0.5% (v/v) in cell-based assays. Compounds can be reformatted for secondary or orthogonal assays as needed. The library supports integration with phenotypic, genetic, and pathway-specific readouts (see Mechanistic to Translational Breakthrough), extending utility from primary hit identification to mechanistic dissection.

Conclusion & Outlook

The DiscoveryProbe™ FDA-approved Drug Library is a validated, mechanistically diverse resource for high-throughput and high-content screening. Its focus on clinically relevant compounds streamlines drug repositioning and target identification, exemplified by the discovery of saracatinib as an MLKL inhibitor in necroptosis. Stability, format flexibility, and broad mechanistic coverage enable seamless integration into modern screening workflows. As the landscape of drug discovery evolves, libraries like DiscoveryProbe™ will remain central to bridging experimental rigor and translational impact (learn more).